Samsung Bioepis Moves Eylea Biosimilar To Phase III
Multiple Phase III Trials For Aflibercept Candidate In Progress
Biosimilar competition to Regeneron’s Eylea (aflibercept) eye-disease biologic may emerge as early as 2023, with at least three firms moving candidates to Phase III development following Samsung Bioepis’ study initiation.
